Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes — MultiPAMS  

Parkinson's Disease Clinical Trial

Official title: Evaluation and Validation of a Multimodal MRI Neuroimaging Method: Application to Differential Diagnosis and Disease Progression in Parkinsonian Syndromes

Status Completed

Clinical Trial Summary

Based on previous promising results, the next step for the validation of a multimodal MRI method in diagnosis and follow up of patients reached by parkinsonian syndromes is (i) to test whether the multimodal neuroimaging is able to discriminate at the individual level, patients with multiple system atrophy parkinsonism (MSA) and patients with idiopathic Parkinson's disease (PD) (ii) to determine whether the method is sensitive to measure changes over time for the two diseases, according to imaging, neuropsychological and other clinical data. Patients will be compared with healthy controls.

Clinical Trial Description

30 patients with PD, 30 patients with MSA and 30 healthy controls will be examined in a 3Tesla MRI. The aim of our project is to demonstrate that our multimodal MRI method can discriminate both diseases with a similar clinical presentation and monitor the progress of the disease. CIC's expertise in recruitment and assessment of patients, and the powers of the INSERM U825 in terms of development and processing in neuroimaging guarantee the feasibility of the project and its successful completion. ;

Related Conditions & MeSH terms

• Atrophy
• Multiple System Atrophy
• Parkinson Disease
• Parkinson's Disease
• Parkinsonian Disorders
• Shy-Drager Syndrome

• NCT number: NCT02428816
• Study type: Interventional
• Source: Institut National de la Santé Et de la Recherche Médicale, France
• Status: Completed
• Phase: N/A
• Start date: January 24, 2013
• Completion date: July 28, 2016